AVITA Medical Expands Wound Care Portfolio Despite Q1 Losses
AVITA Medical Inc. (ASX: AVH) reported Q1 2026 revenue of US$19.3 million, slightly higher than the previous corresponding period, supported by continued demand for its RECELL wound care platform and related products. Gross profit remained stable at US$15.7 million, while operating expenses declined compared to the prior year, reflecting tighter cost management across sales, marketing, and research activities. Despite these improvements, the company recorded a net loss of US$10.6 million as it continued investing in product development, commercialization, and growth initiatives. AVITA strengthened its liquidity position through a new US$60 million senior secured credit facility, including an initial US$50 million drawdown. The company also highlighted ongoing expansion of its RECELL GO and RECELL GO mini platforms, designed to improve wound healing and patient recovery outcomes. Management continues to focus on commercial growth, operational efficiency, and expanding adoption of its regenerative medicine technologies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
AVITA Medical Expands Wound Care Portfolio Despite Q1 Losses
AVITA Medical Inc. (ASX: AVH) reported Q1 2026 revenue of US$19.3 million, slightly higher than the previous corresponding period, supported by continued demand for its RECELL wound care platform and related products. Gross profit remained stable at US$15.7 million, while operating expenses declined compared to the prior year, reflecting tighter cost management across sales, marketing, and research activities. Despite these improvements, the company recorded a net loss of US$10.6 million as it continued investing in product development, commercialization, and growth initiatives. AVITA strengthened its liquidity position through a new US$60 million senior secured credit facility, including an initial US$50 million drawdown. The company also highlighted ongoing expansion of its RECELL GO and RECELL GO mini platforms, designed to improve wound healing and patient recovery outcomes. Management continues to focus on commercial growth, operational efficiency, and expanding adoption of its regenerative medicine technologies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au